In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A

British Journal of Clinical Pharmacology

Volumn 41, Issue 3, 1996, Pages 181-186

  Ring, Barbara J ^a   Binkley, Shelly N ^a   Vandenbranden, Mark ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Clozapine; CYP2C19; CYP2C9; CYP2D6; CYP3A; Cytochrome P450; Drug interactions; Humans; Olanzapine

Indexed keywords

1' HYDROXYBUFURALOL; 4' HYDROXYMEPHENYTOIN; ALPHA HYDROXYMIDAZOLAM; BUFURALOL; CLOZAPINE; CYTOCHROME P450; DRUG METABOLITE; HYDROXYTOLBUTAMIDE; KETOCONAZOLE; MIDAZOLAM; OLANZAPINE; OMEPRAZOLE; PHENYTOIN; QUINIDINE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VITRO STUDY; PRIORITY JOURNAL;

ANTIPSYCHOTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZODIAZEPINES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; KINETICS; MIXED FUNCTION OXYGENASES; PIRENZEPINE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES;

EID: 0029983702     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00180.x     Document Type: Article

References (27)

1. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993; 2: 281-293.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
3. Baldessarine RJ, Frankenberg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324: 746-754.
4. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies. JAMA 1993; 269: 1550-1552.
5. Wrighton SA, Ring BJ. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res 1994; 11: 921-924.
6. Wrighton SA, VandenBranden M, Stevens J, Shipley LA, Ring B. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab Rev 1993; 25: 453-484.
7. Smith DA, Jones BC. Speculations of the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 2089-2098.
8. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Tox 1992; 22: 1-21.
9. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between japanese and caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408.
10. Lledo P. Variations in drug metabolism due to genetic polymorphism. Drug Invest 1993; 5: 19-34.
11. Llerena A, Herriaz AG, Cobaleda J, Johansson I, Dahl ML. Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993; 54: 606-611.
12. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240-245.
13. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752.
14. Guengerich FP. Polymorphism of cytochrome P-450 in humans. Trends Pharmacol Sci 1989; 10: 107.
15. van der Hoeven TA, Coon MJ. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 1974; 249: 6302-6310.
16. Kronbach T, Mathys D, Gut G, Catin T, Meyer UA. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 1987; 162: 24-32.
17. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol 1988; 37: 1137-1144.
18. Segel IH. In Enzyme kinetics: Behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: John Wiley and Sons, 1975: 100-226.
19. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry, 1991; 148: 231-235.
20. Distlerath LM, Reilly PEB, Martin BP, Davis CG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Biol Chem 1985; 260: 9057-9067.
21. Hall SD, Hamman MA, Rettie AE, et al. Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Dispos 1994; 22: 975-978.
22. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-530.
23. Tucker GT. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism. Int J Clin Pharmacol Ther Toxicol 1992; 30: 550-553.
24. Baciewicz AM, Baciewicz FA. Ketoconazole and fluconazole drug interactions. Arch Intern Med 1993; 153: 1970-1976.
25. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1993; 268: 1278-1283.
26. Morike KE, Roden DM. Quinidine-enhanced β-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther 1994; 55: 28-34.
27. Fischer V, Vogels B, Maurer G, Tynes RE. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. J Pharmacol Exp Ther 1992; 260: 1355-1360.